Page 3 of 7
Which participants took part in this study?
Studies have a list of requirements for participants who can enrol (inclusion criteria)
and those who can’t (exclusion criteria). For this study, the main inclusion and
exclusion criteria are listed below.
Women with advanced (stage III or IV) ovarian cancer were included in the
study if they:
• Were at least 18 years old.
• Had a tumour removal surgery.
• Had begun their last cycle of platinum-based chemotherapy within 12
weeks of Day 1.
• Had partial or complete response to platinum-based chemotherapy.
• Received bevacizumab for at least three months before starting the
study.
• Had tumour tissue samples (biopsy) or were willing to undergo a fresh
biopsy before Day 1.
Women were excluded from the study if they had:
• Specific, less-common types of ovarian cancer as assessed by the study
doctor.
• Problems related to the heart, stomach, and/or intestine.
• Higher than normal levels of protein in their urine on Day 1.
• Received a medicine similar to niraparib before starting the study.
• Any other disease(s) or taken any medicine(s) that the study doctor
thought would affect the results of the study.
Overall, 105 women received at least one dose of the study medicine(s). The average
age was 60 years. The youngest participant was 37 years old and the oldest participant
was 82 years old.